Navigation Links
MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award
Date:9/13/2008

Massachusetts General Hospital (MGH) and Harvard Medical School investigator Gary Ruvkun, PhD, is one of three co-recipients of the 2008 Lasker Award for Basic Medical Research. Presented by the Albert and Mary Lasker Foundation, the Lasker Awards are often considered the American version of the Nobel Prize, and many Lasker recipients have gone on to win the Nobel. The award will be presented in New York on Friday, Sept. 26.

Ruvkun and his co-recipients Victor Ambros, PhD, of the University of Massachusetts Medical School and David Baulcombe, PhD, FRS, University of Cambridge in the U.K. are being honored for discovering that tiny molecules of RNA can control the activity of critical genes in animals and plants. Instead of being translated into proteins as messenger RNAs are, single-stranded microRNAs bind to regulatory segments of their target genes' RNA and block gene expression. Current knowledge suggests that microRNAs may control one third of human protein-coding genes.

In the early 1980s Ruvkun and Ambros were both fellows in the Massachusetts Institute of Technology laboratory of Robert Horvitz, PhD, investigating genes that control development in the C. elegans roundworm. They worked together to isolate a gene called lin-14 that operates in concert with a gene called lin-4 to regulate the worms' transition through key developmental stages.

As the two researchers established their own laboratories Ruvkun in the MGH Department of Molecular Biology and Ambros at Harvard they continued collaborating to uncover how the two regulatory genes interacted and made some surprising discoveries. Lin-4 did not block the activity of lin-14 through the protein it coded for but in a manner never seen before by direct interaction between the two genes' RNA strands. These critical RNA molecules also appeared to be extremely small, around 20 nucleotides long. In the meantime Baulcombe was pursuing similar research in plants. His discovery that plant genes could be silenced by the action of tiny RNAs similar to the worm sequences studied by Ruvkun and Ambros implied that the same mechanism operated in plants and animals.

In 2000 Ruvkun's team discovered let-7, another tiny regulatory RNA that shuts down its target gene the same way that lin-4 silences lin-14. They also found that the let-7 RNA sequence had been snipped out of a larger RNA molecule that folds back on itself in a hairpin shape. Later that year Ruvkun published evidence that animals from fish to flies to humans have their own versions of let-7, implying that the mechanism is universal to all but the most primitive animal species.

In 2001 Ruvkun collaborated with Craig Mello, PhD, of UMass and Andrew Fire, PhD, then at the Carnegie Institution, to show that the microRNAs of both lin-4 and let-7 are released from their precursor hairpin RNA molecules by the enzyme Dicer, which is also critical to the RNA interference process that Mello and Fire had discovered and for which they received the 2006 Nobel Prize.

It now appears that the human genome contains between 500 and 1,000 microRNAs involved in a broad range of normal and disease-related activities. Researchers have just begun exploring their potential for the diagnosis, prognosis and treatment of disorders. In addition to continuing investigation of RNA's role in controlling gene expression, Ruvkun's team studies other mechanisms involved in the development, metabolism and longevity of C. elegans, including genes involved in the regulation and storage of fat.

Ruvkun is a professor of Genetics at Harvard Medical School and an investigator at the MGH Center for Computational and Integrative Biology. He holds a bachelor's degree in Biophysics from the University of California at Berkeley and a PhD in Biophysics from Harvard University. Among the many other awards he has received some shared with Ambros and Baulcombe are the Franklin Medal, the Gairdner International Award and the 2008 Warren Triennial Prize from MGH. He is a member of the National Academy of Sciences.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related biology news :

1. Curbing coal emissions alone might avert climate danger, say researchers
2. Researchers develop nano-sized cargo ships to target and destroy tumors
3. Gap junction protein vital to successful pregnancy, researchers find
4. Cortisol and fatty liver: Researchers find cause of severe metabolic disorders
5. Researchers seeking to identify Alzheimers risk focus on specific blood biomarker
6. Childrens National researcher receives ACCP Distinguished Investigator Award
7. New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
8. ISU researchers help map first plant-parasitic nematode genome sequence
9. Collaboration between researchers yields more comprehensive portrait of brain cancer
10. Tel Aviv University researchers create new stem cell screening tool
11. NYU Cancer Institute researcher among first NIH EUREKA award recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... MALDEN, MA (PRWEB) , ... ... ... the leader in Less Exposure Surgery (LES®) Technologies, announced today the next ... the PedFuse Pedicle Screw System platform). In contrast to the competition, SpineFrontier ...
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
Breaking Biology Technology: